Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series

The addition of radiotherapy in neoadjuvant chemotherapy did not improve event-free or overall survival in resectable non-small cell lung carcinoma (NSCLC). Neoadjuvant immunotherapy produced major pathologic response(MPR) rate of up to 45%. The potential synergy between radiotherapy and immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen, Qiang, Yong, Shen, Qin, Zhu, Xi-Xu, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936067/
https://www.ncbi.nlm.nih.gov/pubmed/35321437
http://dx.doi.org/10.3389/fonc.2022.779251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936067/
https://www.ncbi.nlm.nih.gov/pubmed/35321437
http://dx.doi.org/10.3389/fonc.2022.779251

Ejemplares similares